Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

With the approval of Moderna's updated COVID-19 vaccine, doctors are hoping the shots will be available soon and Albertans ...

Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

Moderna has vowed to cut annual R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...

After being criticized for profligate post-pandemic spending, the company is "pacing" itself to focus on launches of key medicines.

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...